These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19324988)

  • 1. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.
    Langley MR; Booker JK; Evans JP; McLeod HL; Weck KE
    J Mol Diagn; 2009 May; 11(3):216-25. PubMed ID: 19324988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
    King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
    Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping.
    Babic N; Haverfield EV; Burrus JA; Lozada A; Das S; Yeo KT
    Clin Chim Acta; 2009 Aug; 406(1-2):143-7. PubMed ID: 19545555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
    Maurice CB; Barua PK; Simses D; Smith P; Howe JG; Stack G
    Clin Chim Acta; 2010 Jul; 411(13-14):947-54. PubMed ID: 20226775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and clinical predictors of warfarin dose requirements in African Americans.
    Cavallari LH; Langaee TY; Momary KM; Shapiro NL; Nutescu EA; Coty WA; Viana MA; Patel SR; Johnson JA
    Clin Pharmacol Ther; 2010 Apr; 87(4):459-64. PubMed ID: 20072124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.
    Limdi NA; Wiener H; Goldstein JA; Acton RT; Beasley TM
    Blood Cells Mol Dis; 2009; 43(1):119-28. PubMed ID: 19297219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
    Perera MA; Gamazon E; Cavallari LH; Patel SR; Poindexter S; Kittles RA; Nicolae D; Cox NJ
    Clin Pharmacol Ther; 2011 Mar; 89(3):408-15. PubMed ID: 21270790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.
    Cini M; Legnani C; Cosmi B; Guazzaloca G; Valdrè L; Frascaro M; Palareti G
    Eur J Clin Pharmacol; 2012 Aug; 68(8):1167-74. PubMed ID: 22349464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing warfarin dose requirements in African-Americans.
    Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
    Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
    Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
    Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
    Limdi NA; Arnett DK; Goldstein JA; Beasley TM; McGwin G; Adler BK; Acton RT
    Pharmacogenomics; 2008 May; 9(5):511-26. PubMed ID: 18466099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.